The Summit is the Premier Industry Event for Defining How New Product Planning Teams and Related Functions Make Informed, Value-Based, Data-Driven Decisions Ensysce Biopharma Leader to Deliver Opening Remarks and Present Case Study on Launching Successful Brands SAN DIEGO, CA / ACCESS Newswire / August 19, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company pioneering novel solutions for severe pain with... Read More

Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory Approval Receives $5.3 Million Installment from NIDA To Support Overdose Protection Program Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2 SAN DIEGO, CA / ACCESS Newswire / August 13, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage... Read More

Productive FDA Meeting Highlights Path Toward Overdose Protection Labeling and 505(b)(2) Regulatory Strategy FDA and Ensysce Aligned on Collaborative Approach to Ensure Product's Full Safety Benefits are Recognized SAN DIEGO, CA / ACCESS Newswire / July 31, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical innovator focused on redefining opioid safety, today... Read More

FDA Protocol Review Completed Rho, Inc. Selected as Clinical Research Partner SAN DIEGO, CA / ACCESS Newswire / July 16, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering novel solutions for severe pain with built-in abuse and overdose protection, today announced the initiation of its pivotal Phase 3 study of PF614, the Company's lead product... Read More

Treatment to Evaluate Effect of Food on Overdose Protection of MPAR Grant Funds from NIDA Accelerating Clinical Development Program SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 24, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today... Read More

Pain Management, RE-Invented: A New Era for Analgesia SAN DIEGO, CA / ACCESS Newswire / June 11, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for abuse and overdose, today announced a world-class panel to discuss the current state of pain therapy at their planned... Read More

PF614-MPAR Moving to Next Stage of Development, Finalizing Drug Formulation Funds Accelerate Path Towards Commercialization SAN DIEGO, CA / ACCESS Newswire / June 4, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced it was awarded... Read More

Receives U.S. Patent for Groundbreaking Treatment for Opioid Use Disorder Clinical Trial on Novel Analgesic, PF614-MPAR, Demonstrates Overdose Protection SAN DIEGO, CA / ACCESS Newswire / May 13, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose,... Read More

Advanced Preparation for New Drug Application SAN DIEGO, CA / ACCESS Newswire / May 12, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for abuse and overdose, today announced it has added Tracy Hysong, CCRA as Senior Director of Regulatory Affairs to its management team.... Read More

SAN DIEGO, CA / ACCESS Newswire / April 24, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 630,376 shares of common stock of... Read More

SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 630,376... Read More

Applies TAAP and MPAR Technology to Produce Novel OUD Treatments Prioritizes Safety and Tolerability for OUD Patients SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for abuse and overdose, today announced it received a Notice of... Read More

Additional Evidence of PF614-MPAR Overdose Protection after Completion of Part 1 of Clinical Study SAN DIEGO, CA / ACCESS Newswire / April 15, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced completion of Part 1 of its second... Read More

SAN DIEGO, CA / ACCESS Newswire / March 31, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has entered into definitive agreements, providing the Company with an aggregate gross proceeds of approximately $1.1 million,... Read More

Analgesic Experts Consider Pain Indications Versus New Classes of Analgesics Panel Discussion Posted to Ensysce's Corporate Website SAN DIEGO, CA / ACCESS Newswire / March 18, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, announced it will... Read More

Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR Groundbreaking Trial on PF614-MPAR Generates Positive Interim Results SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 10, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for... Read More

SAN DIEGO, CA / ACCESS Newswire / March 5, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced its participation in the 37th Annual ROTH Conference being held Sunday, March 16th to Tuesday, March 18th at the Laguna Cliffs Marriott... Read More

NEW YORK , March 3, 2025 /PRNewswire/ -- Today's Marketplace (TMP) is proud to announce a featured interview with Ensysce Biosciences (NASDAQ: ENSC) CEO Dr. Lynn Kirkpatrick and Dr. Neel Pathak, DS , Program Director with Creighton University . The doctors joined TMP's host Jane King to discuss the ongoing issues with opioids for pain management and how "clever chemistry" is being used to introduce safer opioids that are... Read More

Positive Enrollment Progress and Safety Data FDA Attention Establishes Momentum in the Pain Treatment Space SAN DIEGO, CA / ACCESS Newswire / February 5, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced continued subject... Read More

Positive Phase 1b Data Confirms Overdose Protection for Highest Dosage Form of PF614-MPAR SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced interim data from its second clinical trial... Read More

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that on December 20, 2024, it received notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has demonstrated compliance... Read More

Supply Chain Now Fully Secure for PF614-MPAR SAN DIEGO, CA / ACCESSWIRE / December 10, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the receipt of commitment of future supply of GMP nafamostat, a critical component of PF614-MPAR.... Read More

$10 Million Commitment from Specialty Drug Manufacturer to Support Commercialization Efforts SAN DIEGO, CA / ACCESSWIRE / December 4, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the initiation of a strategic partnership with a... Read More

SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that on Friday, December 6, 2024, effective at 12:01 a.m. Eastern Time, it will implement a 1-for-15 reverse split of its common stock. The... Read More

Landmark Overdose Protection Clinical Trial of PF614-MPAR Expects Early Interim Data in 1Q 2025 SAN DIEGO, CA / ACCESSWIRE / November 26, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has treated its first group of... Read More

Awarded $14 Million Multi-Year NIH Grant and Initiated Second Clinical Trial for Breakthrough Therapy PF614-MPAR Submitted Pivotal PF614 Phase 3 Protocol to the FDA for Review SAN DIEGO, CA / ACCESSWIRE / November 12, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for... Read More

SAN DIEGO, CA / ACCESSWIRE / November 7, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has received notice from The Nasdaq Stock Market ("Nasdaq") as described in a decision dated November 5, 2024, that the Company may... Read More

Dr. Lynn Kirkpatrick to Present Latest Clinical Data for PF614 and PF614-MPAR Dr. William Schmidt to Deliver Opening Remarks as Summit Chair SAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced... Read More

SAN DIEGO, CA / ACCESSWIRE / October 2, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today provides a response from Chief Executive Officer, Dr. Lynn Kirkpatrick, regarding recent inquiries from stockholders and other interested parties. Dear... Read More

SAN DIEGO, CA / ACCESSWIRE / September 27, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, has received notice from the listing qualifications department staff of The Nasdaq Stock Market ("Nasdaq") stating that the Company has not regained... Read More

New Data on Opioid Use Disorder Program at Society for Neuroscience Meeting Ensysce CEO Invited Expert Speaker at Formulation & Delivery US 2024 Meeting SAN DIEGO, CA / ACCESSWIRE / September 24, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose,... Read More

Phase 3 Study to Assess PF614 Efficacy in Treating Post-Surgical Pain SAN DIEGO, CA / ACCESSWIRE / September 19, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced it has submitted to the FDA its PF614-301 protocol of the study, "A... Read More

PF614 and PF614-MPAR Highlighted at Symposium on Severe Pain SAN DIEGO, CA / ACCESSWIRE / September 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, has made available two video segments from its August 8 th symposium at the International... Read More

SAN DIEGO, CA / ACCESSWIRE / August 29, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has entered into definitive agreements, providing the Company with aggregate gross proceeds of $5 million, for the issuance and sale... Read More

Next Clinical Trial of FDA Breakthrough Therapy PF614-MPAR Supported by $14 Million Federal Government Grant SAN DIEGO, CA / ACCESSWIRE / August 27, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has received... Read More

Substantial Award Follows FDA Breakthrough Therapy Designation for PF614-MPAR Federal Grant Funding Awarded to Date Now at $40 Million SAN DIEGO, CA / ACCESSWIRE / August 27, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced... Read More

PF614-MPAR Progressing to Phase 1b Study to Verify Both Overdose Protection and Effective Delivery of Oxycodone Opioid Use Disorder Program Advances with Selection of PF9001 as Lead Drug Candidate PF614 Phase 3 Protocol Being Finalized for Submission to FDA SAN DIEGO, CA / ACCESSWIRE / August 14, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing... Read More

PF614 and PF614-MPAR Discussed in Satellite Symposium on Severe Pain SAN DIEGO, CA / ACCESSWIRE / August 7, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, provides a summary of its successful symposium at the International Association for the... Read More

Dr. Lynn Kirkpatrick, CEO, to Introduce Satellite Symposium on Severe Pain: A New Chapter for Safer Analgesics SAN DIEGO, CA / ACCESSWIRE / July 9, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that the Company will host a... Read More

Geoff Birkett, Chief Commercial Officer, Provides Insight Following EPHMRA Meeting SAN DIEGO, CA / ACCESSWIRE / June 27, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, provides takeaways from Geoff Birkett, the Company's Chief Commercial... Read More

Selects Lead Candidate with Abuse Deterrence and Improved Safety Profile to Treat Opioid Use Disorder SAN DIEGO, CA / ACCESSWIRE / June 6, 2024 / Ensysce Biosciences, Inc . (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid misuse, abuse and overdose, today announced the achievement of a critical... Read More

SAN DIEGO, CA / ACCESSWIRE / May 28, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has received notice on May 24, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has demonstrated compliance with the... Read More

New Study to Confirm Overdose Protection Across Full Dosage Range of Breakthrough Therapy Opioid PF614-MPAR SAN DIEGO, CA / ACCESSWIRE / May 20, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the renewal of its collaboration... Read More

PF614's Phase 3 Clinical Plans Affirm the Path to Regulatory Approval FDA Breakthrough Therapy Designation of PF614-MPAR Expedites Clinical Program SAN DIEGO, CA / ACCESSWIRE / May 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today... Read More

Webcast Replay Available on Ensysce's Investor Relations Website SAN DIEGO, CA / ACCESSWIRE / April 19, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the Company's webcast presentation and discussion during the Noble Capital... Read More

Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation and Phase 3 Clinical Plans SAN DIEGO, CA / ACCESSWIRE / March 15, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the fourth quarter and... Read More

SAN DIEGO, CA / ACCESSWIRE / February 27, 2024 / Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq"), as described in a decision dated February 26, 2024, that the Company may continue its listing on The Nasdaq Capital Market tier with an... Read More

PF614-MPAR program receives FDA guidance SAN DIEGO, CA / ACCESSWIRE / February 21, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, is providing an update following its recent meeting with the Food and Drug Administration (FDA) regarding its second product, a ‘Next Generation' opioid analgesic with... Read More

Publication Details Positive Results of Clinical Study PF614-102 SAN DIEGO, CA / ACCESSWIRE / February 15, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (OTC PINK:ENSCW) ("Ensysce" or "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced online publication of its manuscript entitled, "Clinical evaluation of PF614, a novel TAAP (TM) prodrug of oxycodone,... Read More

SAN DIEGO, CA / ACCESSWIRE / February 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 3,601,752 shares of common stock of the... Read More

PF614 Phase 3 Program Expected to Begin Enrollment in Mid-2024 SAN DIEGO, CA / ACCESSWIRE / January 31, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced the completion of a constructive End of Phase 2 meeting with the Food and Drug Administration (FDA) regarding its lead ‘Next... Read More

SAN DIEGO, CA / ACCESSWIRE / December 19, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), today announced that the Company's Special Meeting of Stockholders (the "Special Meeting") to be held on December 20, 2023 at 9:00 a.m. Pacific Time has been postponed due to lack of the required quorum. A quorum consists of one third of the outstanding shares of our common stock (present in person... Read More

Results Reinforce Efficacy of PF614 as a Next Generation Analgesic with Significant Pain Intensity Reduction PF614 Clinical Data Primes FDA Evaluation and Design of Phase 3 Studies in 2024 SAN DIEGO, CA / ACCESSWIRE / December 14, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that its... Read More

Collaboration Aims to Accelerate Development of BupiZenge™, a Novel Pain Treatment for Oral Mucositis Associated with Cancer Treatment SAN DIEGO, CA and STOCKHOLM, SWEDEN / ACCESSWIRE / November 28, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, and OncoZenge AB ("OncoZenge") (STO:ONCOZ), a... Read More

Enrollment Completion Signifies Critical Progress to Phase 3 of PF614 Trial Results Expected in December 2023 SAN DIEGO, CA / ACCESSWIRE / November 16, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that the PF614-201 study, ‘A Randomized, Double-Blind, Placebo-Controlled Crossover... Read More

Additional Funding from Investor Cohort Validates Company's Mission SAN DIEGO, CA / ACCESSWIRE / October 24, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC PINK:ENSCW), a clinical-stage company applying transformative chemistry to improve prescription drug safety, announced today that it has entered into a securities purchase agreement (the "SPA") with investors ("Investors") in the form of... Read More

Poster Presentation to Showcase the Optimization Process of Ensysce's PF614-MPAR Formulation SAN DIEGO, CA / ACCESSWIRE / October 18, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced Dr. Dolly Jacob, Director Integrated Development Services of Quotient Sciences, will present the... Read More

A showcase of PF614 and PF614-MPAR SAN DIEGO, CA / ACCESSWIRE / October 13, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced it has posted to the Company's Corporate and Investor Relations website a video highlighting its PAINWeek Symposium entitled, "Severe Pain, Next Generation Solutions:... Read More

SAN DIEGO, CA / ACCESSWIRE / September 5, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that its management has been invited to present at the H.C. Wainwright 25 th Annual Global Investment Conference (the "conference") taking place in New York, NY on September 11-13, 2023. The... Read More

Progression Toward Full Phase 3 Evaluation of PF614 with Recently Announced IRB Approval of Key Study Protocol SAN DIEGO, CA / ACCESSWIRE / August 11, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the second quarter of 2023. Dr. Lynn Kirkpatrick, Chief Executive... Read More

Approval of Study Represents Progression Toward Full Phase 3 Evaluation of PF614 Study to Assess PF614 Time of Onset for Severe Pain Relief SAN DIEGO, CA / ACCESSWIRE / August 8, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced the Investigational Review Board ("IRB") approval of... Read More

Featured Presentation on ‘Development of a Multi-Pill Abuse Resistant Extended-Release Formulation to Prevent Opioid Overdose' SAN DIEGO, CA / ACCESSWIRE / June 27, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that the company will be providing a poster presentation at the upcoming CRS (Controlled Release... Read More

Chief Medical Officer, Dr. William Schmidt, to Present at the CPDD 85 th Annual Scientific Meeting Chief Commercial Officer, Geoff Birkett, to Present Opening Address at EPHMRA 2023 Annual Conference SAN DIEGO, CA / ACCESSWIRE / June 6, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced two upcoming presentations in... Read More

Recently Completed Successful Ground-Breaking Study on Overdose Protection Recently Completed $7 Million Public Offering SAN DIEGO, CA / ACCESSWIRE / May 15, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the first quarter of 2023 following the recently completed,... Read More

SAN DIEGO, CA / ACCESSWIRE / May 12, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today the closing of the previously announced public offering of an aggregate of 1,800,876 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to... Read More

Corporate Update Call to be Held Tuesday, April 11, 2023 SAN DIEGO, CA / ACCESSWIRE / March 30, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today reported financial results for the fourth quarter and full year of 2022. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented,... Read More

SAN DIEGO, CA / ACCESSWIRE / February 15, 2023 / Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that by decision dated February 14, 2023, a Nasdaq Hearings Panel (the "Panel") granted the Company's request for continued listing on The Nasdaq Stock Market ("Nasdaq"),... Read More

SAN DIEGO, CA / ACCESSWIRE / February 14, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced a Poster Presentation will be presented by Geoff Birkett, Chief Commercial Officer of Ensysce, at the Annual NIH HEAL Meeting on February 22, 2023, in... Read More

SAN DIEGO, CA / ACCESSWIRE / February 3, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has entered into a definitive agreement for the purchase and sale of 3,571,431 shares of the Company's common stock at a purchase price of $0.84 per share of common... Read More

SAN DIEGO, CA / ACCESSWIRE / February 1, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that its Board of Directors has declared a dividend of 0.001 of a share of newly-designated Series A Preferred Stock, par value $0.0001 per... Read More

SAN DIEGO, CA / ACCESSWIRE / January 11, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today issued a letter to shareholders from Chief Executive Officer, Dr. Lynn Kirkpatrick. Dear Fellow Shareholders, I want to take this opportunity to thank our... Read More

PF614-MPAR will be the Industry's First Overdose Protection Pain Product SAN DIEGO, CA / ACCESSWIRE / December 19, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced data demonstrating the overdose protection of its drug product,... Read More

SAN DIEGO, CA / ACCESSWIRE / December 7, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC),(OTC PINK: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the pricing of an underwritten public offering of 2,900,000 shares of its common stock (or common stock equivalents in lieu thereof) and... Read More

Completion of Trial Represents Continuing Progress Towards Development of the Industry's First Overdose Protection Pain Product SAN DIEGO, CA / ACCESSWIRE / December 5, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC),(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has... Read More

Acute pain indication may be appropriate, with potential to significantly shorten development path SAN DIEGO, CA / ACCESSWIRE / November 14, 2022 / Ensysce Biosciences Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety focused on reducing abuse and overdose, today announced that it received written guidance... Read More

Announces Timing of Corporate Update Call Ensysce Biosciences Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety focused on reducing abuse and overdose, today announced positive topline results from a human abuse potential (HAP) study for PF614. PF614 is a new class of analgesia, a Trypsin Activated... Read More

Critical Study to Support Abuse Deterrent Labeling Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety focused on reducing abuse and overdose, today announced the first subjects dosed in the PF614-104 study, ‘A Randomized, Double-blind, Placebo and Active-Controlled, Crossover Study to... Read More

Ensysce Biosciences, Inc. (NASDAQ: ENSC) (OTC Pink: ENSCW) ("Ensysce" or the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced management's participation in the LD Micro Main Event XV conference being held from October 25-27, 2022 at the Luxe Sunset Boulevard Hotel in Bel Air, California. The Company's Chief... Read More

Oral Opioid Abuse Being Explored for PF614 Data From Trial Supports Abuse Deterrent Labeling, Designed to Measure the Potential for Drug Liking Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety focused on reducing abuse and overdose, today announced the initiation of PF614-104, ‘A... Read More

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that management will present during Benzinga's All Access investor event taking place Friday, September 23, 2022. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, is scheduled to host... Read More

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the results of the special meeting of stockholders held September 8, 2022. This meeting was held virtually, and the following resolutions were submitted and adopted by the stockholders: The... Read More

Special Meeting to be Held Virtually on Thursday, September 8 th at 9:00 AM PT Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today reminds shareholders to vote on or before the upcoming annual shareholder meeting on Thursday, September 8 th at 9:00 AM... Read More

Partnership further expedites Ensysce's development pipeline Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC) (OTC PINK: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, and Quotient Sciences, a drug development and manufacturing accelerator, today announced a partnership to support the development and clinical testing of PF614-MPAR.... Read More

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the launch of the new Ensysce website at www.ensysce.com . The Company's updated website highlights the TAAP TM and MPAR TM technology platforms, the depth of the team, and our truly unique... Read More

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced its participation in the following upcoming conferences: PAINWeek Conference 2022, September 6 - September 9, 2022, in Las Vegas, NV . Dr. Lynn Kirkpatrick, Chief Executive Officer, to chair a... Read More

Completion of Clinical Portion Represents Critical Milestone Towards Commercialization Nasal Opioid Abuse Being Explored for PF614 Data From Trial Expected in September 2022 Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has... Read More

Call to be Held Today, August 17, 2022 at 11am ET Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance focused on reducing abuse and overdose, today released an updated investor presentation to its investor relations website accessible via https://ir.ensysce.com/ . The... Read More

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance focused on reducing abuse and overdose, today reported financial results for the second quarter 2022. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "With a recently completed $8 million financing, we... Read More

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today that it has completed its previously announced private placement under a securities purchase agreement with institutional investors ("Investors") for senior secured convertible notes (the... Read More

~ BE Study of PF614 Represents Critical Progress Toward FDA Approval ~ ~ Supports the 505(b)(2) Regulatory Path for Clinical Development of PF614 ~ Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today the data from the Part B, Bioequivalence... Read More